CVS Health (NYSE:CVS) finance chief Thomas Cowhey is set to step down amid the company's ongoing turnaround efforts led by ...

CVS Health Corp Chief Financial Officer Thomas Cowhey intends to step down from his position, Bloomberg News reported on ...

CVS Health's chief financial officer, Thomas Cowhey, intends to step down, Bloomberg News reported on Monday, amid the health ...

CVS faces pressures from rising medical costs, but promising guidance, stable finances, and low valuations suggest strong ...

CVS Health Corp. continues to fight a civil lawsuit that accuses the corporation and its retail pharmacists of wrongfully ...

In a motion to dismiss most claims, attorneys for the Woonsocket, R.I.-based company argue the DOJ failed to provide key ...

The company announced Monday that the MMR vaccine would be available at more than 500 locations of CVS Pharmacy stores and ...

CVS Health is offering measles vaccines to people who live in Pennsylvania after two cases of the disease have been confirmed ...

CVS Health is a BUY. Undervalued with growth potential, it outshines competitors despite sector challenges. See more on CVS ...

Although elevated after 2023 acquisitions, CVS’ financial position remains manageable, in our opinion, and investors should note that CVS intends to maintain a solid investment-grade credit rating.

In a report released today, Charles Rhyee from TD Cowen reiterated a Buy rating on CVS Health (CVS – Research Report), with a price target of ...

One quarter into 2025, CVS Health has risen the most of any stock in the S&P 500, with a share price that has popped 50% ...